Uterine artery embolization for uterine fibroids
Institute for Clinical Systems Improvement
Record ID 32003000572
This review aims to assess the available evidence on the effectiveness of uterine artery embolization for uterine fibroids.
Authors' recomendations: With regard to uterine artery embolization (UAE) for uterine fibroids, the ICSI Technology Assessment Committee finds: UAE is generally safe in appropriately selected patients. Patients must be aware of the potential for premature menopause following UAE. Hysterectomy was performed in 1.6% to 4.5% of patients following UAE (although not always attributable to failure of UAE). The goal of UAE is amelioration of symptoms. In case series completed to date, 85% to 96% of UAE patients interviewed reported a reduction in bleeding at up to 12 months following UAE and 61% to 93% have reported a reduction in bulk-related symptoms. (Conclusion Grade III). A reduction in fibroid size of 17% to 58% has been reported. Since the fibroids are still present, pain and pressure symptoms may persist. Uterine volume decreased by 13% to 52% at up to 1 year following UAE. There are limited long-term follow-up data. A patient registry has been established. There are insufficient data on the safety of pregnancy following UAE; based on current evidence the procedure should be performed only for women not desiring future pregnancy.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.icsi.org/index.asp
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
- Embolization, Therapeutic
Organisation Name: Institute for Clinical Systems Improvement
Contact Address: 8009 34th Avenue South, Suite 1200, Bloomington, MN, USA. Tel: +1 952 814 7060; Fax: +1 952 858 9675
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Systems Improvement (ICSI)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.